Direct compression of Tinctura Auranti Veterinary Grade API into scored oral tablets requires prior adsorption of the hydroalcoholic extract onto a dry carrier because the native tincture contains residual ethanol in the range of 60–70% v/v and co-extracted essential oil components that act as lubricant contaminants under sustained compaction. On production-scale rotary presses, the tincture is sprayed onto a dry adsorbent composed of microcrystalline cellulose PH102 and colloidal silicon dioxide at a 3:1 ratio. The liquid is metered through an atomising nozzle at 0.5–1.0 kg/min into a 500 L ribbon blender running at 20–30 rpm. The resulting adsorbate is vacuum-dried at 35–40°C until loss on drying is ≤3.0% w/w as measured by a halogen moisture analyser at 105°C. Residual moisture above this threshold increases punch-tip sticking on the tablet press, while an over-dried blend below 1.0% w/w can develop capping defects because of elastic energy accumulation in the compact. The batch-to-batch essential oil content of the tincture varies with peel origin and extraction season; therefore the adsorbent ratio is adjusted within 3:1 to 4:1 after each raw-material HPLC assay to maintain equivalent compressibility. Manufacturing is conducted under FDA 21 CFR Part 211 for finished veterinary dosage forms.

The following adsorbate preparation window is used as a release specification before compression.

Final tablet compression is performed on a 19-station rotary press fitted with 8 mm flat bevel punches and chromium nitride-coated punch tips. Hardness is maintained at 60–90 N, friability is held at ≤1.0% under Ph. Eur. 2.9.7, and mass uniformity is checked under Ph. Eur. 2.9.5. Disintegration testing under Ph. Eur. 2.9.1 uses water at 37°C and requires disintegration within 15 minutes. Dissolution is performed under Ph. Eur. 2.9.3 in 900 mL of 0.1 M hydrochloric acid at 37°C with paddle speed 50 rpm; the release acceptance criterion is Q≥75% at 45 minutes. The finished dosage form is a scored veterinary oral tablet intended for calves and foals, with a 500 mg target mass and a break-line subdivision score that is evaluated by Ph. Eur. 2.9.6.

What Restricts Terminal Sterilisation of Tinctura Auranti in Parenteral Veterinary Formulations?

Terminal steam sterilisation at 121°C for 15 minutes is generally incompatible with crude tincture-derived parenteral solutions because limonene, linalool and related monoterpenes undergo thermal oxidation to hydroperoxides that can precipitate as visible particulates after cooling. The native ethanol content is therefore reduced by vacuum-assisted solvent exchange to a final formulation ethanol concentration of 10–20% v/v. The exchange is performed in a jacketed glass-lined reactor at 40°C and –0.8 bar relative pressure. The resulting aqueous co-solvent solution is passed through a 1.0 μm glass-fibre pre-filter and then a 0.2 μm PVDF membrane filter. PVDF is used instead of polysulfone or PES because residual terpene alcohols can foul the membrane and reduce flux below the validated threshold for filling line operation. The filtered bulk solution is held in a sterile stainless-steel surge tank under nitrogen blanketing; dissolved oxygen is maintained below 1.0 mg/L to slow the oxidative degradation of the remaining essential oil fraction. Aseptic filling is conducted in an ISO 14644-1 cleanroom under a Grade A local zone.

Endotoxin control follows Ph. Eur. 5.1.1, with limits of ≤0.5 EU/mL for intrauterine infusions and ≤0.25 EU/mL for intramuscular or intramammary products. Sterility testing follows Ph. Eur. 2.6.1 by membrane filtration. Published data for this specific crude tincture in multidose parenteral veterinary products are limited; therefore the dosage form is confined to filtered aqueous-co-solvent solutions rather than terminally steamed presentations. Ethanol concentrations above 20% v/v are avoided for intramuscular injection because of injection-site irritation and increased haemolytic risk. The final product is filled under aseptic conditions into sterilised 100 mL multidose vials with bromobutyl rubber stoppers and aluminium overseals. Vial headspaces are purged with nitrogen to residual oxygen below 1.0% v/v, measured by a headspace oxygen analyser, before capping. The target species are cattle and swine, and the route is subcutaneous or intramuscular with a maximum injected volume of 10 mL per site.

When hard gelatin capsules are required for companion-animal oral administration, the fill mass is produced by liquid adsorption onto a mixture of pregelatinised starch and anhydrous dibasic calcium phosphate in a mixer-granulator fitted with a chopper at 1000–1500 rpm. The tincture is added at 1.0–2.0% w/w of the fill mass through a spray lance, and mixing continues until the angle of repose is below 35° determined by Ph. Eur. 2.9.36. Encapsulation is performed on an intermittent tamping-pin machine with a filling chamber RH of 30–40%; this narrow humidity window prevents residual ethanol and moisture in the fill mass from plasticising the gelatin shell, a failure mode that produces cap splitting and star-cracking at the dome. The fill mass is controlled at 350–450 mg for size 0 or size 1 hard capsules, depending on the required veterinary dose. Batch uniformity of capsule mass is checked under Ph. Eur. 2.9.5, with an acceptance value corresponding to ≤5% RSD for 20 capsules. Disintegration testing under Ph. Eur. 2.9.1 requires ≤30 minutes in 0.1 M hydrochloric acid; dissolution is performed under Ph. Eur. 2.9.3 with Apparatus 2 at 50 rpm and a criterion of Q≥75% at 45 minutes. The finished product is a companion-animal oral capsule for dogs and cats, presented as a 250 mg fill mass capsule.

Dry Powder Blending of a Hydroalcoholic Tincture onto Lactose Monohydrate Carriers

Oral powders for drinking-water or feed-top application are prepared by spraying Tinctura Auranti onto lactose monohydrate 200 mesh or glucose monohydrate in a ribbon blender. The liquid addition is set at 2.0–5.0% w/w and delivered at 0.5–1.0 kg/min through an air-atomising nozzle placed above the moving powder bed. The blender speed is kept at 20–30 rpm; higher shear accelerates the formation of moist agglomerates on the ribbon impeller, while lower speed leaves solvent-rich pockets that later harden into lumps. After spraying, the blend is passed through a 1.0 mm sieve and mixed for a further 10 minutes. Homogeneity is assessed by a validated thief-probe protocol with 10 samples drawn from different zones; the coefficient of variation must remain below 5.0% RSD. The final powder is filled into foil-lined pouches of 100 g and 1 kg under nitrogen flush to residual oxygen below 1.0% v/v. The terminal product is a free-flowing oral powder intended for mixing into drinking water for poultry and swine; absence of visible agglomerates is confirmed by sieving through a 1.5 mm screen before release.

When the Tincture Is Used as a Binder Liquid in High-Shear Granulation

Wet granulation with Tinctura Auranti as a binder liquid begins by diluting the tincture with purified water to a strength of 15–25% w/w and verifying binder viscosity at 80–120 mPa·s and 25°C with a rotational viscometer. The dry blend of microcrystalline cellulose, maize starch, and dicalcium phosphate is charged to a high-shear granulator; the main impeller runs at 150–300 rpm and the side chopper at 1000–1500 rpm. The binder is delivered by a peristaltic pump through a 0.8 mm nozzle. The granulation endpoint is defined by wet-mass moisture of 8–12% w/w and an impeller torque increase of 20–30% over the dry-blend baseline. Over-wetting produces a paste that blocks the wet sieve and extends drying time, whereas under-wetting generates fines that segregate during hopper discharge and sachet filling. The wet granules are dried in a fluid-bed dryer with inlet air at 50–60°C until loss on drying reaches 2.0–3.5% w/w; product temperature is maintained below 40°C to reduce loss of volatile essential oil components. Dried granules are screened through 0.8 mm and 1.4 mm sieves. The target fraction between 0.5 mm and 1.0 mm should represent at least 80% w/w of the yield to provide acceptable flow into single-dose sachets. The final oral granules are filled into 10 g or 25 g unit-dose sachets for foals and calves. Moisture content is confirmed by Karl Fischer titration under Ph. Eur. 2.5.12 with a limit of ≤3.5% w/w, and mass uniformity is tested under Ph. Eur. 2.9.5.

Medicated Feed Premix Homogeneity and Carry-Over Limits in Multi-Species Rations

In-feed application of Tinctura Auranti Veterinary Grade API is carried out with a carrier-based premix manufactured under Regulation (EU) 2019/4 and FDA 21 CFR Part 225. The premix is built by stepwise dilution in a double-cone blender. A 1:10 dilution of the tincture-adsorbate with calcium carbonate or wheat middlings is mixed for 15 minutes; a second 1:10 dilution is then blended for 10 minutes. The final tincture concentration in the premix is set at 0.5–2.0% w/w, and the premix is incorporated into complete feed at 0.5–2.0 kg per tonne. Mixing uniformity is measured by sampling 10 locations with a grain probe, and the coefficient of variation for the marker component must remain below 5.0% using a validated HPLC marker assay. Segregation is controlled by keeping the premix particle size between 0.3 mm and 1.0 mm and by avoiding storage relative humidity above 60%. The finished premix is a dry free-flowing powder for inclusion in ruminant and swine rations; it is filled into 25 kg paper bags with a polyethylene liner. Release is contingent on a tincture marker content of 90.0–110.0% of label claim by a stability-indicating HPLC assay under VICH GL3. The carry-over limit into a subsequent non-target feed batch is established in cleaning validation and is set at ≤1.0% of the preceding batch concentration.

For multi-dose oral drench production, Tinctura Auranti is compounded into clear to slightly opalescent hydroalcoholic liquids with a final ethanol concentration of 10–25% v/v. The solution is prepared in a stainless-steel mixing vessel with a high-torque propeller stirrer at 100–300 rpm. The tincture is added to a co-solvent blend of purified water and glycerol, and the pH is adjusted to 3.5–5.0 with citric acid monohydrate or sodium citrate dihydrate. The pH window is critical because the natural flavonoid glycosides in the tincture are hydrolytically unstable above pH 5.5, whereas pH below 3.0 increases the concentration of free limonene and can produce turbidity. The solution is filtered through a 10 μm polypropylene cartridge before filling. Filling is carried out at 20–25°C and maximum relative humidity of 50% to reduce water uptake and phase separation in the ethanol-containing vehicle. The finished product is filled into amber 1 L high-density polyethylene or glass bottles with tamper-evident closures; the amber container is selected after photostability testing under VICH GL3 for the packaged solution. Preservative efficacy testing under Ph. Eur. 5.1.3 is required for the multidose container, with acceptance criteria of log 1 reduction for bacteria at 24 hours and no increase from the initial count at 28 days for Candida albicans and Aspergillus brasiliensis. The solution is intended as an oral drench for calves, sheep, and goats. The field dose is based on the authorised veterinary product classification and is not assigned solely from this raw-material specification. Filled containers are passed through an in-line checkweigher and cap torque tester; torque is set at 0.8–1.2 N·m on 28 mm closures.